Home > Healthcare > Pharmaceuticals > Finished Drug Form > Progesterone Market

Progesterone Market Trends

  • Report ID: GMI8310
  • Published Date: Feb 2024
  • Report Format: PDF

Progesterone Market Trends

  • Hormonal imbalances, such as polycystic ovary syndrome (PCOS), endometriosis, and irregular menstrual cycles, are becoming more prevalent globally. For instance, as per the WHO, polycystic ovary syndrome (PCOS) affects an estimated 8% to 13% of reproductive-aged women. Similarly, as per the CDC, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of U.S. women of reproductive age.
     
  • These conditions often require progesterone therapy to manage symptoms and restore hormonal balance. Thus, increasing prevalence of hormonal disorders has emerged as a significant driver of the market.
     
  • Additionally, as awareness grows and diagnoses improve, the demand for progesterone-based treatments will further continue to rise, thereby driving the market growth.
     

However, side effects and safety concerns represent a significant restraint for the market growth. These side effects range from mild symptoms such as nausea, headaches, and breast tenderness to more severe complications like blood clots and mood changes. Additionally, safety concerns regarding long-term use and potential risks, particularly in specific patient populations such as pregnant women or individuals with certain medical conditions may hamper the adoption rates, thereby hindering the industry growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of progesterone reached USD 1.3 billion in 2023 and is set to record 12.7% CAGR between 2024 and 2032, attributed to the increasing incidence of hormonal disorders such as polycystic ovary syndrome (PCOS) and endometriosis.

The natural segment dominated the market with 58.2% share in 2023, because of its bio-identical nature that closely mimics the progesterone produced by the human body, making it a preferred choice for many patients seeking hormone replacement therapy.

North America market share was 39.2% of the revenue share in 2023, due to the region's advanced healthcare infrastructure, extensive R&D initiatives, and the widespread adoption of progesterone-based therapies for various medical conditions.

Alkem Laboratories Ltd., Aquatic Group, Bionpharma Inc., Cadila Pharmaceuticals, Cipla Inc., Estrellas Life Sciences Private Limited., Eli Lily & Company, Glenmark Pharmaceuticals Ltd., Insud Pharma S.L.U., Lupin, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.

Progesterone Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 353
  • Countries covered: 19
  • Pages: 210
 Download Free Sample